Short Interest in Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Rises By 70.6%

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) was the target of a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 7,083 shares, an increase of 70.6% from the July 30th total of 4,153 shares. Based on an average daily volume of 848 shares, the short-interest ratio is currently 8.4 days. Currently, 0.7% of the company’s shares are short sold.

Addex Therapeutics Stock Up 0.9%

ADXN stock opened at $3.88 on Monday. The business has a 50 day moving average price of $5.60 and a 200 day moving average price of $6.36. The stock has a market cap of $4.77 million, a price-to-earnings ratio of -0.65 and a beta of 1.50. Addex Therapeutics has a fifty-two week low of $3.73 and a fifty-two week high of $12.05.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Addex Therapeutics in a report on Monday, July 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Addex Therapeutics currently has an average rating of “Sell”.

Addex Therapeutics Company Profile

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.